Thermo Fisher Scientific Inc. $TMO Shares Sold by Marathon Asset Management Ltd

Marathon Asset Management Ltd lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 85,546 shares of the medical research company’s stock after selling 7,256 shares during the quarter. Thermo Fisher Scientific comprises about 1.9% of Marathon Asset Management Ltd’s investment portfolio, making the stock its 19th largest position. Marathon Asset Management Ltd’s holdings in Thermo Fisher Scientific were worth $49,602,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TMO. Wellington Management Group LLP lifted its holdings in Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock worth $1,309,292,000 after buying an additional 1,270,191 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock worth $720,576,000 after purchasing an additional 825,649 shares during the last quarter. Finally, Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.4%

Shares of Thermo Fisher Scientific stock opened at $448.34 on Wednesday. The business’s fifty day moving average price is $483.39 and its two-hundred day moving average price is $540.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a market capitalization of $166.61 billion, a P/E ratio of 24.65, a PEG ratio of 1.96 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm earned $5.15 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Robert W. Baird cut their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Citigroup lifted their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $616.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.